These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 19138505

  • 1. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis.
    Schermer T, Chavannes N, Dekhuijzen R, Wouters E, Muris J, Akkermans R, van Schayck O, van Weel C.
    Respir Med; 2009 Apr; 103(4):542-51. PubMed ID: 19138505
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Early intervention with inhaled corticosteroids in subjects with rapid decline in lung function and signs of bronchial hyperresponsiveness: results from the DIMCA programme.
    den Otter JJ, van Schayck CP, Folgering HT, van den Boom G, Akkermans RP, van Weel C.
    Eur J Gen Pract; 2007 Apr; 13(2):89-91. PubMed ID: 17534745
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
    van Overveld FJ, Demkow U, Górecka D, de Backer WA, Zielinski J.
    J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K, Hara K, Yoneda K, Kanauchi T, Kagiyama N, Tokunaga D, Takayanagi N, Ubukata M, Sugita Y.
    Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.
    Tashkin DP.
    Am J Med; 2006 Oct; 119(10 Suppl 1):63-72. PubMed ID: 16996901
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
    Decramer M, Rutten-van Mölken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A.
    Lancet; 2006 Oct; 365(9470):1552-60. PubMed ID: 15866309
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.
    Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, Yao WZ, Ma LJ, Xia QK, Gao Y, Zhong NS, PANTHEON study committee.
    COPD; 2013 Apr; 10(2):164-71. PubMed ID: 23061828
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.